<DOC>
	<DOCNO>NCT02166463</DOCNO>
	<brief_summary>This randomized phase III trial study brentuximab vedotin combination chemotherapy see well work compare combination chemotherapy alone treat young patient newly diagnose Hodgkin lymphoma . Combinations biological substance brentuximab vedotin may able carry cancer-killing substance directly Hodgkin lymphoma cell . Drugs use chemotherapy , doxorubicin hydrochloride , bleomycin sulfate , vincristine sulfate , etoposide , prednisone , cyclophosphamide , work different way stop growth cancer cell , either kill cell , stop dividing , stop spread . It yet know combination chemotherapy effective without brentuximab vedotin treat Hodgkin lymphoma .</brief_summary>
	<brief_title>Brentuximab Vedotin Combination Chemotherapy Treating Younger Patients With Newly Diagnosed Hodgkin Lymphoma</brief_title>
	<detailed_description>PRIMARY OBJECTIVES : I . To assess event free survival ( EFS ) novel regimen incorporate brentuximab vedotin ( Bv ; Adcetris ) chemotherapy backbone doxorubicin ( Adriamycin ) ( doxorubicin hydrochloride ) , vincristine ( vincristine sulfate ) , etoposide , prednisone cyclophosphamide ( Bv-AVEPC ) newly diagnose high-risk classical Hodgkin lymphoma ( cHL ) compare treated Adriamycin , bleomycin sulfate , vincristine sulfate , etoposide , prednisone , cyclophosphamide ( ABVE-PC ) . SECONDARY OBJECTIVES : I . To determine whether children/adolescents high-risk cHL treat Bv-AVEPC high rate early response ( determine fludeoxyglucose F 18 [ FDG ] -positron emission tomography [ PET ] ) reduction protocol direct radiation therapy ( RT ) compare treated ABVE-PC . II . To compare rate neuropathy ( &gt; = grade 3 ) among patient treat Bv-AVEPC ( experimental arm ) patient treat ABVE-PC ( standard arm ) . TERTIARY OBJECTIVES : I . To validate compare Childhood Hodgkin International Prognostic Score ( CHIPS ) conventional Ann Arbor Stage ( Stages II B bulk , III B , IV A B ) predict outcome high-risk childhood cHL . II . To determine incidence preferentially express antigen melanoma ( PRAME ) testis-specific antigen Epstein-Barr virus ( EBV ) - cHL tumor incidence EBV antigen ( Epstein-Barr nuclear antigen 1 [ EBNA1 ] , Epstein-Barr virus latent membrane protein 1 [ LMP1 ] , large multifunctional peptidase 2 [ LMP2 ] ) EBV+ cHL tumor , goal develop strategy integrate cellular therapy treatment newly diagnose high-risk cHL . ( Biology ) III . To incorporate qualitative visual FDG-PET response-directed treatment algorithm explore quantitative FDG-PET compute tomography ( CT ) definition tumor burden response incorporation next generation pediatric cHL risk-stratification scheme . ( Imaging ) IV . To evaluate reduction normal tissue irradiation associate current treatment approach compare volume historic involved field radiation therapy ( IFRT ) field . ( Radiation Therapy ) V. To evaluate EFS pattern relapse follow protocol-specified RT utilization treatment volume . ( Radiation Therapy ) VI . To characterize extent chemotherapy induce peripheral neuropathy ( CIPN ) , report patient parent proxy , serial administration Functional Assessment Cancer Therapy-Gynecologic Oncology Group-Neurotoxicity ( FACT-GOG-NTX ) . ( Patient Reported Outcomes [ PRO ] Peripheral Neuropathy Health-Related Quality Life ) VII . To describe Health-Related Quality Life ( HRQL ) consequences peripheral neuropathy time correlate total neuropathy scale score individual item Child Health Ratings Inventories ( CHRIs ) -Global scale ( e.g. , physical health , pain , emotional functioning ) . ( PRO Peripheral Neuropathy Health-Related Quality Life ) VIII . To perform cross validation FACT-GOG-NTX Total Neuropathy Score-Pediatric Vincristine ( TNS-PV ) determine performance measure use brentuximab vedotin limit institutional approach child adolescent cHL . ( PRO Peripheral Neuropathy Health-Related Quality Life ) IX . To assess resource use cost implication Bv combination chemotherapy radiotherapy ( RT ) newly diagnose high-risk cHL child adolescent . ( Economic ) OUTLINE : Patients randomize 1 2 treatment arm . ARM I ( ABVE-PC ) : Patients receive doxorubicin hydrochloride intravenously ( IV ) 1-15 minute day 1-2 , bleomycin sulfate IV 10 minute subcutaneously ( SC ) day 1 8 , vincristine sulfate IV 1 minute day 1 8 , etoposide IV 60-120 minute day 1-3 , prednisone orally ( PO ) twice daily ( BID ) day 1-7 , cyclophosphamide IV 30-60 minute day 1 2 . ARM II ( Bv-AVEPC ) : Patients receive brentuximab vedotin IV 30 minute day 1 . Patients also receive doxorubicin hydrochloride , etoposide , prednisone , cyclophosphamide Arm I vincristine sulfate IV 1 minute day 8 . In arm , treatment repeat every 21 day 5 course absence disease progression unacceptable toxicity . After completion study treatment , patient follow 3 , 6 , 9 , 12 , 18 , 24 , 30 , 36 , 48 month .</detailed_description>
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>Hodgkin Disease</mesh_term>
	<mesh_term>Cyclophosphamide</mesh_term>
	<mesh_term>Liposomal doxorubicin</mesh_term>
	<mesh_term>Etoposide phosphate</mesh_term>
	<mesh_term>Doxorubicin</mesh_term>
	<mesh_term>Prednisone</mesh_term>
	<mesh_term>Etoposide</mesh_term>
	<mesh_term>Bleomycin</mesh_term>
	<mesh_term>Vincristine</mesh_term>
	<mesh_term>Podophyllotoxin</mesh_term>
	<mesh_term>Antibodies</mesh_term>
	<mesh_term>Immunoglobulins</mesh_term>
	<mesh_term>Antibodies , Monoclonal</mesh_term>
	<mesh_term>Immunoconjugates</mesh_term>
	<mesh_term>Cortisone acetate</mesh_term>
	<mesh_term>Cortisone</mesh_term>
	<criteria>Patients newly diagnose , pathologically confirm cHL meet one follow Ann Arbor stage eligible : Stage IIB bulk Stage IIIB Stage IVA Stage IVB If study eligibility stag uncertain , consultation Imaging Radiation Oncology Core ( IROC ) Rhode Island ( RI ) may obtain prior study enrollment Creatinine clearance radioisotope glomerular filtration rate ( GFR ) &gt; = 70 mL/min/1.73 m^2 serum creatinine base age/gender follow : 2 &lt; 6 year : male 0.8 mg/dL , female 0.8 mg/dL 6 &lt; 10 year : male 1 mg/dL , female 1 mg/dL 10 &lt; 13 year : male 1.2 mg/dL , female 1.2 mg/dL 13 &lt; 16 year : male 1.5 mg/dL , female 1.4 mg/dL &gt; = 16 year : male 1.7 mg/dL , female 1.4 mg/dL Total bilirubin = &lt; 1.5 x upper limit normal ( ULN ) age Serum glutamic oxaloacetic transaminase ( SGOT ) ( aspartate transaminase [ AST ] ) serum glutamate pyruvate transaminase ( SGPT ) ( alanine transaminase [ ALT ] ) &lt; 2.5 x upper limit normal ( ULN ) age Shortening fraction &gt; = 27 % echocardiogram , ejection fraction &gt; = 50 % radionuclide angiogram Forced expiratory volume 1 second ( FEV1 ) /forced vital capacity ( FVC ) &gt; 60 % pulmonary function test ( PFT ) , unless due large mediastinal mass Hodgkin lymphoma ( HL ) For child unable cooperate PFTs , criterion : evidence dyspnea rest , exercise intolerance , pulse oximetry read &gt; 92 % room air All patient and/or parent legal guardian must sign write informed consent All institutional , Food Drug Administration ( FDA ) , National Cancer Institute ( NCI ) requirement human study must meet Patients nodular lymphocytepredominant HL Patients immunodeficiency exist prior diagnosis , primary immunodeficiency syndrome , organ transplant recipient child current systemic immunosuppressive agent eligible Patients pregnant ; ( negative pregnancy test require female patient childbearing potential ) Lactating female plan breastfeed Sexually active patient reproductive potential agree use effective contraceptive method duration study participation 30 day last dose chemotherapy Patients know positive human immunodeficiency virus ( HIV ) eligible Patients receive previous chemotherapy radiation therapy eligible Patients receive systemic corticosteroid within 28 day enrollment protocol , except specify , eligible</criteria>
	<gender>All</gender>
	<minimum_age>2 Years</minimum_age>
	<maximum_age>18 Years</maximum_age>
	<verification_date>November 2016</verification_date>
</DOC>